OxyContin Opens Door For Broader Peds Opioids Market
This article was originally published in Scrip
Executive Summary
In giving Purdue Pharma its blessing to market its extended-release oxycodone drug OxyContin in pediatric patients 11-16 years to control severe pain, the FDA on Aug. 13 said to expect more opioids to enter the market for children and teenagers.